# CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

> **NCT04653493** · PHASE1 · UNKNOWN · sponsor: **Sabz Biomedicals** · enrollment: 22 (estimated)

## Conditions studied

- Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
- Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

## Interventions

- **BIOLOGICAL:** CD19 CAR engineered autologous T-cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT04653493
- **Lead sponsor:** Sabz Biomedicals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04653493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04653493, "CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04653493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*